Literature DB >> 16138187

Osteoblast-derived PTHrP is a physiological regulator of bone formation.

T John Martin1.   

Abstract

Parathyroid hormone-related protein (PTHrP) acts as a paracrine regulator in several tissues, and its physiological roles also extend to bone. In this issue of the JCI, Miao et al. demonstrate that osteoblast-specific ablation of Pthrp in mice results in osteoporosis and impaired bone formation both in vivo and ex vivo. These mice recapitulate the phenotype of mice with haploinsufficiency of Pthrp. The findings demonstrate that PTHrP plays a central role in the physiological regulation of bone formation, by promoting recruitment and survival of osteoblasts, and probably plays a role in the physiological regulation of bone resorption, by enhancing osteoclast formation. This has implications for both our understanding of the pathogenesis of osteoporosis and its treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138187      PMCID: PMC1193889          DOI: 10.1172/JCI26239

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Authors:  Y L Ma; R L Cain; D L Halladay; X Yang; Q Zeng; R R Miles; S Chandrasekhar; T J Martin; J E Onyia
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

2.  A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide.

Authors:  H Jüppner; A B Abou-Samra; M Freeman; X F Kong; E Schipani; J Richards; L F Kolakowski; J Hock; J T Potts; H M Kronenberg
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

3.  Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.

Authors:  Dengshun Miao; Bin He; Yebin Jiang; Tatsuya Kobayashi; Maria A Sorocéanu; Jenny Zhao; Hanyi Su; Xinkang Tong; Norio Amizuka; Ajay Gupta; Harry K Genant; Henry M Kronenberg; David Goltzman; Andrew C Karaplis
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

4.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

5.  A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression.

Authors:  L J Suva; G A Winslow; R E Wettenhall; R G Hammonds; J M Moseley; H Diefenbach-Jagger; C P Rodda; B E Kemp; H Rodriguez; E Y Chen
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

6.  Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Caren Gundberg; Adolfo Garcia-Ocana; Andrew F Stewart
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

Review 7.  Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions.

Authors:  J J Orloff; D Reddy; A E de Papp; K H Yang; N E Soifer; A F Stewart
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

8.  Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.

Authors:  Charles A Frolik; Elwood C Black; Ricky L Cain; Julie H Satterwhite; Patricia L Brown-Augsburger; Masahiko Sato; Janet M Hock
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

9.  Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice.

Authors:  Dengshun Miao; Jiarong Li; Yingben Xue; Hanyi Su; Andrew C Karaplis; David Goltzman
Journal:  Endocrinology       Date:  2004-04-16       Impact factor: 4.736

10.  Immunohistochemical detection of parathyroid hormone-related protein in human fetal epithelia.

Authors:  J M Moseley; J A Hayman; J A Danks; D Alcorn; V Grill; J Southby; M A Horton
Journal:  J Clin Endocrinol Metab       Date:  1991-09       Impact factor: 5.958

View more
  38 in total

1.  Connexin43 interacts with βarrestin: a pre-requisite for osteoblast survival induced by parathyroid hormone.

Authors:  Nicoletta Bivi; Virginia Lezcano; Milena Romanello; Teresita Bellido; Lilian I Plotkin
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

2.  Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases.

Authors:  Tianhong Pan; Eliza L S Fong; Mariane Martinez; Daniel A Harrington; Sue-Hwa Lin; Mary C Farach-Carson; Robert L Satcher
Journal:  Cancer Lett       Date:  2015-05-21       Impact factor: 8.679

3.  Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP1-17.

Authors:  J S Frieling; G Shay; V Izumi; S T Aherne; R G Saul; M Budzevich; J Koomen; C C Lynch
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  The C-terminal fragment of parathyroid hormone-related peptide promotes bone formation in diabetic mice with low-turnover osteopaenia.

Authors:  D Lozano; L Fernández-de-Castro; S Portal-Núñez; A López-Herradón; S Dapía; E Gómez-Barrena; P Esbrit
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

5.  Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo.

Authors:  P W M Ho; A Goradia; M R Russell; A M Chalk; K M Milley; E K Baker; J A Danks; J L Slavin; M Walia; B Crimeen-Irwin; R A Dickins; T J Martin; C R Walkley
Journal:  Oncogene       Date:  2014-07-21       Impact factor: 9.867

6.  Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.

Authors:  Thomas Dean; Jean-Pierre Vilardaga; John T Potts; Thomas J Gardella
Journal:  Mol Endocrinol       Date:  2007-09-13

Review 7.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

8.  Parathyroid hormone-related protein regulates osteoclast inhibitory lectin expression via multiple signaling pathways in osteoblast-like cells.

Authors:  Fang Zheng; Hui Liang; Rui Liu; Jin-Xing Quan; Xiao-Xia Li; Chen-Lin Dai; Gang Guo; Jing-Yu Zhang; Bao-Li Wang
Journal:  Endocrine       Date:  2008-11-06       Impact factor: 3.633

9.  Runx2-Smad signaling impacts the progression of tumor-induced bone disease.

Authors:  Xuhui Zhang; Jacqueline Akech; Gillian Browne; Stacey Russell; John J Wixted; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Int J Cancer       Date:  2014-08-05       Impact factor: 7.396

10.  Dynamic and structural properties of the skeleton in hypoparathyroidism.

Authors:  Mishaela R Rubin; David W Dempster; Hua Zhou; Elizabeth Shane; Thomas Nickolas; James Sliney; Shonni J Silverberg; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.